Ionis Subsidiary Akcea Launches $125M IPO, Led By Cooley
Akcea Therapeutics Inc., a late-stage biotech being spun out of Ionis Pharmaceuticals Inc., on Tuesday set terms on an estimated $125 million initial public offering, under guidance from Cooley LLP, joining...To view the full article, register now.
Already a subscriber? Click here to view full article